^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    FoundationOne® CDx

    Company:
    Roche
    Type:
    FDA Approved (PMA)
    Related tests:
    5d
    ADELA: Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (clinicaltrials.gov)
    P3, N=240, Recruiting, MedSIR | Active, not recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation • ESR1 mutation
    |
    FoundationOne® CDx • Guardant360® CDx • FoundationOne® Liquid CDx
    |
    everolimus • dexamethasone • Orserdu (elacestrant)
    5d
    A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. (clinicaltrials.gov)
    P1, N=14, Recruiting, PMV Pharmaceuticals, Inc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 Y220C
    |
    FoundationOne® CDx • MSK-IMPACT • MSK-ACCESS
    |
    metformin • rezatapopt (PC14586) • midazolam hydrochloride
    5d
    Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study. (PubMed, JCO Precis Oncol)
    Our findings suggest significant clinical, pathologic, and molecular correlations in an Australian cohort of advanced melanoma treated with ICIs. Patients with NF1 mutation exhibited higher TMB, which was associated with improved response to ICIs.
    Journal • Tumor mutational burden • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • NF1 (Neurofibromin 1)
    |
    TMB-H • BRAF mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • NRAS wild-type
    |
    FoundationOne® CDx
    11d
    Potential Utility of Comprehensive Genomic Profiling to Predict Venous Thromboembolism in Patients with Solid Cancer. (PubMed, J Thromb Haemost)
    The current exploratory study identified several genomic variants potentially associated with a high risk of cancer-associated VTE, which may indicate potential clinical utility of comprehensive genomic profiling for accurate prediction of VTE events in cancer patients.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • NOTCH1 (Notch 1)
    |
    FoundationOne® CDx
    13d
    NCI 10211: Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • MSI (Microsatellite instability)
    |
    HER-2 positive • TP53 mutation • MSI-H/dMMR
    |
    FoundationOne® CDx
    |
    irinotecan • berzosertib (M6620)
    14d
    A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition • Tumor mutational burden • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type
    |
    FoundationOne® CDx
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    19d
    ASPiRATION-2 Liquid: An observational cohort study to assess the impact of longitudinal molecular profiling using circulating tumour DNA (ctDNA) in patients with advanced Non-Small Cell Lung Cancer (NSCLC) after failure of genomically targeted therapy. (ACTRN12626000225314)
    P=N/A, N=500, Not yet recruiting, The University of Sydney
    New trial • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NRG1 (Neuregulin 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • BRAF mutation • MET exon 14 mutation • RET mutation • ROS1 fusion • NRG1 fusion
    |
    FoundationOne® CDx • TruSight Oncology 500 Assay
    19d
    Assessing the Impact of Comprehensive Genomic Profiling on Therapeutic Selection for Advanced Solid Tumors in Portugal. (PubMed, Curr Oncol)
    The FRONTAL study highlighted the clinical relevance of CGP in advanced solid tumors. Over half of the patients had actionable alterations, a quarter had therapy changes based on CGP results, and improved disease outcome was observed in approximately 15% of the cohort.
    Journal
    |
    FoundationOne® CDx • FoundationOne® Liquid CDx • FoundationOne® Heme CDx
    22d
    Genetic mutations in recurrent and/or metastatic nasal carcinoma: A pathological comparison based on the Japanese national genomic profiling database. (PubMed, Otolaryngol Pol)
    These findings underscore the importance of genomic stratification in rare nasal carcinomas. <br><br><b></b> CGP reveals key genetic drivers in nasal carcinoma, supporting its role in precision oncology and informing future subtype-specific therapeutic approaches.
    Clinical • Journal • Tumor mutational burden
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • KMT2D (Lysine Methyltransferase 2D) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2)
    |
    FoundationOne® CDx
    25d
    NCI-2017-00831: Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC (clinicaltrials.gov)
    P2, N=93, Terminated, M.D. Anderson Cancer Center | Trial completion date: Dec 2027 --> Feb 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2027 --> Feb 2026; <75% participation
    Trial completion date • Trial termination • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation
    |
    FoundationOne® CDx • Guardant360® CDx • cobas® EGFR Mutation Test v2 • therascreen® EGFR RGQ PCR Kit
    |
    Pozenveo (poziotinib)
    26d
    Comprehensive Genomic Profiling Across Diverse Solid Tumors: A Real-World Experience From India With FoundationOne®CDx Testing. (PubMed, Cureus)
    F1CDx recommended FDA-approved therapies relevant to the tumor type in 41.7% of cases and tumor-agnostic or off-label therapies in 50.4%. Conclusions F1CDx profiling identified a broad spectrum of actionable alterations across diverse tumors, highlighting its strong potential to expand therapeutic options and advance precision oncology in real-world Indian practice.
    Journal • Real-world evidence
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    TP53 mutation • PIK3CA mutation • KRAS G12D • RET fusion • KRAS G12 • IDH1 R132
    |
    FoundationOne® CDx
    28d
    ROMANCE (2025-521319-38-00)
    P1/2, N=150, Not yet recruiting, Gruppo Oncologico Dell'Italia Meridionale
    New P1/2 trial • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
    |
    BRAF V600E • BRAF V600
    |
    FoundationOne® CDx
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • irinotecan • Lonsurf (trifluridine/tipiracil)